[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[$zldpf](/topic/$zldpf)

### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$zldpf/c:line/m:sentiment.svg)  
[Sentiment 24-Hour Chart Data](/topic/$zldpf/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Month**: XX% -X%  
**1-Year High**: XXX% on 2025-06-13  
**1-Year Low**: XX% on 2025-06-24  

**Most Supportive Themes**
- **GLP-1 Agonists' Broad Benefits:** (40%) The potential of GLP-1 receptor agonists in treating various conditions beyond diabetes and obesity, including cardiovascular health, and neurodegenerative diseases.
- **GLP-1 Drug Development and Investment:** (30%) The increasing interest and investment in GLP-1 drugs and related research, including new studies and developments by companies like Eli Lilly and Amgen.
- **Weight Loss and Hormonal Benefits:** (15%) The impact of GLP-1 drugs on weight loss and the potential for hormonal benefits, such as increased testosterone levels.
  
**Most Critical Themes**
- **GLP-1 Drug Risks and Drawbacks:** (15%)  Concerns about side effects, long-term efficacy, and potential risks associated with GLP-1 drugs and compounded alternatives.
  
Network engagement breakdown:  
| Network | Positive | %   | Neutral | %   | Negative | %   |
| ------- | -------- | -   | ------- | -   | -------- | -   |
| X       | XXXXX    | XX% | XXXXX   | XX% | XXXXX    | XX% |
|         |          |     |         |     |          |     |
| Total   | XXXXX    | XX% | XXXXX   | XX% | XXXXX    | XX% |